Carey R M, Thorner M O, Ortt E M
J Clin Invest. 1979 Apr;63(4):727-35. doi: 10.1172/JCI109356.
This study was designed to investigate the possible role of dopaminergic mechanisms in the control of the renin-angiotensin-aldosterone system in normal man. Six normal male subjects in metabolic balance at 150 meq sodium, 60 meq potassium constant intake received the specific dopamine antagonist, metoclopramide, 10 mg i.v. or placebo followed by angiotensin II infusion 1 h later on 2 consecutive days. Metoclopramide increased plasma aldosterone concentration from 8.2+/-2.2 to 21.0+/-3.3 ng/100 ml (P < 0.005) and plasma prolactin concentration from 18.0+/-4.0 to 91.7+/-4.0 ng/ml (P < 0.001) within 15 min of its administration. At 1 h, plasma aldosterone and prolactin concentrations remained elevated at 16.8+/-2.1 ng/100 ml (P < 0.01) and 86.8+/-15.9 ng/ml (P < 0.005), respectively. Angiotensin II at 2, 4, and 6 pmol/kg per min further increased plasma aldosterone concentration to 27.2+/-3.4, 31.9+/-5.7, and 36.0+/-6.7 ng/100 ml (P < 0.02), respectively. Placebo did not alter plasma aldosterone or prolactin concentrations, but angiotensin II increased plasma aldosterone concentration to 13.7+/-2.4, 19.0+/-1.9, and 23.3+/-3.2 ng/100 ml (P < 0.005). The increment of plasma aldosterone concentration in response to angiotensin II was similar after metoclopramide or placebo. The six subjects also received the dopamine agonist, bromocriptine, 2.5 mg or placebo at 6 p.m., midnight, and 6 a.m. followed by angiotensin II infusion on 2 consecutive d. Bromocriptine suppressed prolactin to <3 ng/ml. After placebo, plasma aldosterone concentration increased from 5.2+/-1.4 to 12.3+/-1.7, 17.2+/-2.2, and 21.8+/-3.5 ng/100 ml (P < 0.01) and after bromocriptine from 7.2+/-1.0 to 14.7+/-3.0, 19.8+/-3.2, and 23.4+/-1.6 ng/100 ml (P < 0.001) with each respective angiotensin II dose. No difference in the response to angiotensin II after bromocriptine or placebo was observed. Plasma renin activity, free 11-hydroxycorticoid concentration, and serum potassium concentration were unchanged by metoclopramide or bromocriptine. The results suggest that aldosterone production is under maximum tonic dopaminergic inhibition which can be overridden with stimulation by angiotensin II in normal man.
本研究旨在探讨多巴胺能机制在正常男性肾素 - 血管紧张素 - 醛固酮系统调控中可能发挥的作用。6名正常男性受试者在钠摄入量为150 meq、钾摄入量为60 meq且摄入量恒定的代谢平衡状态下,连续2天先静脉注射10 mg特异性多巴胺拮抗剂甲氧氯普胺或安慰剂,1小时后再输注血管紧张素II。甲氧氯普胺给药后15分钟内,血浆醛固酮浓度从8.2±2.2 ng/100 ml增至21.0±3.3 ng/100 ml(P < 0.005),血浆催乳素浓度从18.0±4.0 ng/ml增至91.7±4.0 ng/ml(P < 0.001)。1小时时,血浆醛固酮和催乳素浓度仍分别维持在较高水平,为16.8±2.1 ng/100 ml(P < 0.01)和86.8±15.9 ng/ml(P < 0.005)。下午2点、4点和6点以每分钟2、4和6 pmol/kg的速度输注血管紧张素II,可使血浆醛固酮浓度分别进一步增至27.2±3.4、31.9±5.7和36.0±6.7 ng/100 ml(P < 0.02)。安慰剂未改变血浆醛固酮或催乳素浓度,但血管紧张素II可使血浆醛固酮浓度增至13.7±2.4、19.0±1.9和23.3±3.2 ng/100 ml(P < 0.005)。甲氧氯普胺或安慰剂给药后,血管紧张素II诱导的血浆醛固酮浓度增量相似。这6名受试者还在下午6点、午夜和凌晨6点接受了2.5 mg多巴胺激动剂溴隐亭或安慰剂,随后连续2天输注血管紧张素II。溴隐亭可将催乳素抑制至<3 ng/ml。安慰剂给药后,随着每次血管紧张素II剂量的增加,血浆醛固酮浓度从5.2±1.4 ng/100 ml增至12.3±1.7、17.2±2.2和21.8±3.5 ng/100 ml(P < 0.01);溴隐亭给药后,血浆醛固酮浓度从7.2±1.0 ng/100 ml增至14.7±3.0、19.8±3.2和23.4±1.6 ng/100 ml(P < 0.001)。未观察到溴隐亭或安慰剂给药后对血管紧张素II的反应存在差异。甲氧氯普胺或溴隐亭对血浆肾素活性、游离11 - 羟皮质类固醇浓度和血清钾浓度无影响。结果表明,在正常男性中,醛固酮的产生受到最大程度的多巴胺能紧张性抑制,而血管紧张素II的刺激可克服这种抑制。